The cannabis industry has recently become big business. In 2018, according to Consumer Reports, for the first time in history, the cannabis industry is worth $10 billion. The implications of cannabis testing results continue to gain importance and we need to find innovative methods of testing for cannabis.

Update: This event has now ended. The on-demand replay is now available.

We get a lot of questions about the specifics of succeeding with microsampling technologies in the bioanalytical lab, as well as some larger questions around applications in pharma, in clinical trials, and across the spectrum of clinical trials. This is your chance to have your questions answered, including the ones you didn't even know you had.

This year’s conference of the European Federation for Exploratory Medicines Development (EUFEMED), held May 15 – 17 in Lyon, France, turned a spotlight on “The Changing Landscape of Early Medicines Development.” This included a presentation by Hugues Chanteux on some exciting new work he’s done with his team at UCB Pharma, an innovative pharma company that has done much to move forward the science of blood microsampling.

Some of the biggest challenges in running a clinical trial involve finding and engaging the right participants. Patient recruitment for clinical trials can be complicated. It sometimes leads to research delays or abandonment because of insufficient participation.

The drug development process can be simpler. Recruitment, retention, and adherence / compliance can be improved. Significant points of friction can be removed. Powerful changes can be as simple as the way blood samples are taken.

Have you ever been asked to participate in a clinical trial for a new drug or medical device? Have you turned down such an offer because it seemed like too much trouble? Extra doctor’s appointments, lost hours at work, trips to the lab for bloodwork or urinalysis, keeping a diary… perhaps it doesn't seem to be worth the effort.